In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

US-based investment firm takes controlling stake in Opella, while France's government moves to ensure the company remains in ...

GSK cuts 2024 vaccine sales forecast for second time this year Strong specialty medicines offset lower vaccine sales - CEO Q3 EPS beats market expectations Shares down 3.9% at 0958 GMT Oct 30 ...

GSK spun off Haleon to form a new consumer healthcare entity, driven by activist investor pressure and its underperforming share price. Haleon’s financials show steady growth with 2023 revenues ...

Mehta said HUL's focus would continue to ensure uninterrupted supplies of COVID relevant portfolio and meeting the demand arising out of evolving consumer needs ...

GSK, along with several other drug manufacturing companies ... The FTC and others argued that generic medications save the ...

Shalini Kumar has joined Kenvue as Head - Consumer Experience. Shalini was earlier with Halenon as Area Media Lead for ...

Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products. Read More on GB:GSK: GSK NewsMORE Related Stocks Indices ...

The Oral Hygiene market presents a robust growth outlook with evolving consumer preferences ... Johnson & Johnson, Unilever, ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.

GSK CEO Emma Walmsley's bet on blockbuster RSV vaccine, Arexvy, has hit a snag in recent months after the U.S. public health ...